RSS-Feed abonnieren
DOI: 10.1055/s-0031-1273405
© Georg Thieme Verlag KG Stuttgart · New York
S3-Leitlinie „Aszites, spontan bakterielle Peritonitis, hepatorenales Syndrom”
German S 3-Guideline ”Ascites, spontaneous bacterial peritonitis, hepatorenal syndrome”Publikationsverlauf
Publikationsdatum:
01. Juni 2011 (online)

I. Diagnostik des Aszites I.1. Einleitung: Ursachen des Aszites I.2. Wann soll eine diagnostische Aszitespunktion durchgeführt werden? I.3. Technik, Komplikationen und Kontraindikationen der Aszitespunktion I.3.1 Sollen Gerinnungsfaktoren vor einer Aszitespunktion substituiert werden? I.3.2 Welche Kontraindikationen zur Aszitespunktion bestehen? I.4. Diagnostik bei Aszitespunktion I.4.1 Welche Untersuchungen sind obligater Bestandteil der initialen Aszitespunktion? I.4.2 Welche Untersuchungen sind optionaler Bestandteil einer Aszitespunktion? I.4.3 Welche zytologischen Untersuchungen sollen durchgeführt werden? I.5. Spezifische Diagnostik bei Patienten mit Aszites bedingt durch ein Budd-Chiari-Syndrom (BCS) oder sinusoidales Obstruktionssyndrom I.6. Welche Parameter weisen auf eine sekundäre bakterielle Peritonitis hin? II. Therapie des Aszites II.1. Wann bedarf ein Patient mit Aszites einer Therapie? II.2. Was ist die Rolle der nicht medikamentösen Basistherapie? II.3. Wie wird die medikamentöse Therapie des Aszites durchgeführt? II.4. Wie wird der therapierefraktäre und rezidivierende Aszites behandelt? III. Spontan bakterielle Peritonitis III.1. Einleitung: Definition, Inzidenz und Prognose einer spontanbakteriellen Peritonitis (SBP) bzw. eines Bakteraszites III.2. Wann und wie sollte eine Primärprophylaxe einer SBP durchgeführt werden? III.3. Wie sollte eine SBP behandelt werden? III.4. Wie sollte die Sekundärprophylaxe und Nachsorge einer SBP aussehen ? IV. Hepatorenales Syndrom IV.1. Einleitung: Definition IV.2. Welchen Stellenwert hat die Albumingabe in der Therapie des HRS? IV.3. Welchen Stellenwert haben Vasokonstriktoren in der Therapie des HRS? IV.4. Gibt es einen Stellenwert des transjugulären intrahepatischen portosystemischen Shunts (TIPS) bei HRS? IV.5. Wann ist ein Nierenersatzverfahren beim HRS indiziert und welchen Stellenwert haben Leberersatzverfahren? IV.6. Wie beeinflusst das HRS die Indikation zur und den Verlauf nach Lebertransplantation? V. Hepatischer Hydrothorax V.1. Einleitung: Definition V.2. Welche Untersuchungen sind zur Abklärung eines hepatischen Hydrothoraxes notwendig? V.3. Wie sollten Patienten mit hepatischem Hydrothorax therapiert werden? V.4. Wie sollten Patienten mit rezidivierendem hepatischem Hydrothorax therapiert werden? V.5. Spontan bakterielles Empyem (SBEM) V.5.1 Wie wird ein spontan bakterielles Empyem (SBEM) diagnostiziert und therapiert? Abkürzungsverzeichnis Literatur
Die vorliegende Leitlinie wurde erstellt durch die Deutsche Gesellschaft für Verdauungs- und Stoffwechselkrankheiten (Leitung: Prof. Dr. med. A. L. Gerbes, Medizinische Klinik und Poliklinik II, Klinikum der Universität München Großhadern; Prof. Dr. T. Sauerbruch, Medizinische Klinik und Poliklinik I, Universitätsklinikum Bonn) in Zusammenarbeit mit folgenden Fachgesellschaften/Organisationen:
Deutsche Gesellschaft für Allgemein- und Viszeralchirurgie (DGAV) Deutsche Gesellschaft für Ernährungsmedizin (DGEM) Deutsche Gesellschaft für Infektiologie (DGI) Deutsche Gesellschaft für Nephrologie (DGfN) Deutsche Gesellschaft für Pathologie (DGP) Deutsche Röntgengesellschaft (DRG) Lebertransplantierte Deutschland e. V.
Literatur
- 1
Runyon B A.
Management of adult patients with ascites due to cirrhosis.
Hepatology.
2004;
39
841-856
MissingFormLabel
- 2
Arroyo V, Fernandez-Esparrach G, Gines P.
Diagnostic approach to the cirrhotic patient with ascites.
J Hepatol.
1996;
25 (Suppl 1)
35-40
MissingFormLabel
- 3
Cardenas A, Chopra S.
Chylous ascites.
Am J Gastroenterol.
2002;
97
1896-1900
MissingFormLabel
- 4
Almakdisi T, Massoud S, Makdisi G.
Lymphomas and chylous ascites: review of the literature.
Oncologist.
2005;
10
632-635
MissingFormLabel
- 5
Runyon B A.
Early events in spontaneous bacterial peritonitis.
Gut.
2004;
53
782-784
MissingFormLabel
- 6
Castellote J.
Spontaneous bacterial peritonitis and reagent strips.
Hepatology.
2007;
46
1667-1668
; author reply 1669 – 1670
MissingFormLabel
- 7
Jeffries M A, Stern M A, Gunaratnam N T et al.
Unsuspected infection is infrequent in asymptomatic outpatients with refractory ascites
undergoing therapeutic paracentesis.
Am J Gastroenterol.
1999;
94
2972-2976
MissingFormLabel
- 8
Evans L T, Kim W R, Poterucha J J et al.
Spontaneous bacterial peritonitis in asymptomatic outpatients with cirrhotic ascites.
Hepatology.
2003;
37
897-901
MissingFormLabel
- 9
Romney R, Mathurin P, Ganne-Carrie N et al.
Usefulness of routine analysis of ascitic fluid at the time of therapeutic paracentesis
in asymptomatic outpatients. Results of a multicenter prospective study.
Gastroenterol Clin Biol.
2005;
29
275-279
MissingFormLabel
- 10
Robert Koch-Institut .
Anforderungen der Hygiene bei Operationen und anderen invasiven Eingriffen – Mitteilung
der Kommission für Krankenhaushygiene und Infektionsprävention am Robert Koch-Institut.
Bundesgesundheitsblatt.
2000;
43
644-648
MissingFormLabel
- 11
Schlottmann K, Gelbmann C, Grune S et al.
A new paracentesis needle for ascites and pleural effusion compared with the venous
indwelling catheter. A prospective, randomized study.
Med Klin.
2001;
96
321-324
MissingFormLabel
- 12
Gines P, Arroyo V, Rodes J.
Treatment of ascites and renal failure in cirrhosis.
Baillieres Clin Gastroenterol.
1989;
3
165-186
MissingFormLabel
- 13
Shaheen N J, Grimm I S.
Comparison of the Caldwell needle/cannula with Angiocath needle in large volume paracentesis.
Am J Gastroenterol.
1996;
91
1731-1733
MissingFormLabel
- 14
Boccia S, Rollo V, Accorsi L et al.
Paracentesis: a new needle for an old technique.
Endoscopy.
1991;
23
83-84
MissingFormLabel
- 15
Nazeer S R, Dewbre H, Miller A H.
Ultrasound-assisted paracentesis performed by emergency physicians vs. the traditional
technique: a prospective, randomized study.
Am J Emerg Med.
2005;
23
363-367
MissingFormLabel
- 16
Sakai H, Sheer T A, Mendler M H et al.
Choosing the location for non-image guided abdominal paracentesis.
Liver Int.
2005;
25
984-986
MissingFormLabel
- 17
Cattau Jr E L, Benjamin S B, Knuff T E et al.
The accuracy of the physical examination in the diagnosis of suspected ascites.
JAMA.
1982;
247
1164-1166
MissingFormLabel
- 18
Irshad A, Ackerman S J, Anis M et al.
Can the smallest depth of ascitic fluid on sonograms predict the amount of drainable
fluid?.
J Clin Ultrasound.
2009;
37
440-444
MissingFormLabel
- 19
De Gottardi A, Thevenot T, Spahr L et al.
Risk of complications after abdominal paracentesis in cirrhotic patients: a prospective
study.
Clin Gastroenterol Hepatol.
2009;
7
906-909
MissingFormLabel
- 20
Martinet O, Reis E D, Mosimann F.
Delayed hemoperitoneum following large-volume paracentesis in a patient with cirrhosis
and ascites.
Dig Dis Sci.
2000;
45
357-358
MissingFormLabel
- 21
Arnold C, Haag K, Blum H E et al.
Acute hemoperitoneum after large-volume paracentesis.
Gastroenterology.
1997;
113
978-982
MissingFormLabel
- 22
Grabau C M, Crago S F, Hoff L K et al.
Performance standards for therapeutic abdominal paracentesis.
Hepatology.
2004;
40
484-488
MissingFormLabel
- 23
Pache I, Bilodeau M.
Severe haemorrhage following abdominal paracentesis for ascites in patients with liver
disease.
Aliment Pharmacol Ther.
2005;
21
525-529
MissingFormLabel
- 24
Lin C H, Shih F Y, Ma M H et al.
Should bleeding tendency deter abdominal paracentesis?.
Dig Liver Dis.
2005;
37
946-951
MissingFormLabel
- 25
Mallory A, Schaefer J W.
Complications of diagnostic paracentesis in patients with liver disease.
JAMA.
1978;
239
628-630
MissingFormLabel
- 26
Webster S T, Brown K L, Lucey M R et al.
Hemorrhagic complications of large volume abdominal paracentesis.
Am J Gastroenterol.
1996;
91
366-368
MissingFormLabel
- 27
Minocha A.
A fatal case of paracentesis.
Am J Gastroenterol.
1999;
94
856
MissingFormLabel
- 28
McVay P A, Toy P T.
Lack of increased bleeding after paracentesis and thoracentesis in patients with mild
coagulation abnormalities.
Transfusion.
1991;
31
164-171
MissingFormLabel
- 29
Runyon B A.
Paracentesis of ascitic fluid. A safe procedure.
Arch Intern Med.
1986;
146
2259-2261
MissingFormLabel
- 30
Mannucci P M.
Abnormal hemostasis tests and bleeding in chronic liver disease: are they related?
No.
J Thromb Haemost.
2006;
4
721-723
MissingFormLabel
- 31
Angeloni S, Nicolini G, Merli M et al.
Validation of automated blood cell counter for the determination of polymorphonuclear
cell count in the ascitic fluid of cirrhotic patients with or without spontaneous
bacterial peritonitis.
Am J Gastroenterol.
2003;
98
1844-1848
MissingFormLabel
- 32
Rimola A, Garcia-Tsao G, Navasa M et al.
Diagnosis, treatment and prophylaxis of spontaneous bacterial peritonitis: a consensus
document. International Ascites Club.
J Hepatol.
2000;
32
142-153
MissingFormLabel
- 33
Albillos A, Cuervas-Mons V, Millan I et al.
Ascitic fluid polymorphonuclear cell count and serum to ascites albumin gradient in
the diagnosis of bacterial peritonitis.
Gastroenterology.
1990;
98
134-140
MissingFormLabel
- 34
Jones S R.
The absolute granulocyte count in ascites fluid. An aid to the diagnosis of spontaneous
bacterial peritonitis.
West J Med.
1977;
126
344-346
MissingFormLabel
- 35
Runyon B A.
Low-protein-concentration ascitic fluid is predisposed to spontaneous bacterial peritonitis.
Gastroenterology.
1986;
91
1343-1346
MissingFormLabel
- 36
Llach J, Rimola A, Navasa M et al.
Incidence and predictive factors of first episode of spontaneous bacterial peritonitis
in cirrhosis with ascites: relevance of ascitic fluid protein concentration.
Hepatology.
1992;
16
724-727
MissingFormLabel
- 37
Guarner C, Sola R, Soriano G et al.
Risk of a first community-acquired spontaneous bacterial peritonitis in cirrhotics
with low ascitic fluid protein levels.
Gastroenterology.
1999;
117
414-419
MissingFormLabel
- 38
Canete N, Erice E, Bargallo A et al.
Natural history of spontaneous bacterial peritonitis: A longitudinal study in 263
cirrhotic patients after the first ascites decompensation.
J Hepatol.
2007;
46
S90-S91
MissingFormLabel
- 39
Pare P, Talbot J, Hoefs J C.
Serum-ascites albumin concentration gradient: a physiologic approach to the differential
diagnosis of ascites.
Gastroenterology.
1983;
85
240-244
MissingFormLabel
- 40
Runyon B A, Montano A A, Akriviadis E A et al.
The serum-ascites albumin gradient is superior to the exudate-transudate concept in
the differential diagnosis of ascites.
Ann Intern Med.
1992;
117
215-220
MissingFormLabel
- 41
Dittrich S, Yordi L M, Mattos A A.
The value of serum-ascites albumin gradient for the determination of portal hypertension
in the diagnosis of ascites.
Hepatogastroenterology.
2001;
48
166-168
MissingFormLabel
- 42
Runyon B A, Canawati H N, Akriviadis E A.
Optimization of ascitic fluid culture technique.
Gastroenterology.
1988;
95
1351-1355
MissingFormLabel
- 43
Castellote de J, Xiol X, Verdaguer R et al.
Comparison of two ascitic fluid culture methods in cirrhotic patients with spontaneous
bacterial peritonitis.
Am J Gastroenterol.
1990;
85
1605-1608
MissingFormLabel
- 44
Bobadilla M, Sifuentes J, Garcia-Tsao G.
Improved method for bacteriological diagnosis of spontaneous bacterial peritonitis.
J Clin Microbiol.
1989;
27
2145-2147
MissingFormLabel
- 45
Caly W R, Strauss E.
A prospective study of bacterial infections in patients with cirrhosis.
J Hepatol.
1993;
18
353-358
MissingFormLabel
- 46
Kuiper J J, Buuren H R, Man de R A.
Limited role for routine ascites culture as a diagnostic tool for spontaneous bacterial
peritonitis in the era of prophylactic antibiotics.
J Hepatol.
2007;
46
S96
MissingFormLabel
- 47
Butani R C, Shaffer R T, Szyjkowski R D et al.
Rapid diagnosis of infected ascitic fluid using leukocyte esterase dipstick testing.
Am J Gastroenterol.
2004;
99
532-537
MissingFormLabel
- 48
Castellote van J, Lopez C, Gornals J et al.
Rapid diagnosis of spontaneous bacterial peritonitis by use of reagent strips.
Hepatology.
2003;
37
893-896
MissingFormLabel
- 49
Sapey T, Kabissa D, Fort E et al.
Instant diagnosis of spontaneous bacterial peritonitis using leukocyte esterase reagent
strips: Nephur-Test vs. MultistixSG.
Liver Int.
2005;
25
343-348
MissingFormLabel
- 50
Thevenot T, Cadranel J F, Nguyen-Khac E et al.
Diagnosis of spontaneous bacterial peritonitis in cirrhotic patients by use of two
reagent strips.
Eur J Gastroenterol Hepatol.
2004;
16
579-583
MissingFormLabel
- 51
Vanbiervliet G, Rakotoarisoa C, Filippi J et al.
Diagnostic accuracy of a rapid urine-screening test (Multistix8SG) in cirrhotic patients
with spontaneous bacterial peritonitis.
Eur J Gastroenterol Hepatol.
2002;
14
1257-1260
MissingFormLabel
- 52
Campillo B, Richardet J P, Dupeyron C.
Diagnostic value of two reagent strips (Multistix 8 SG and Combur 2 LN) in cirrhotic
patients with spontaneous bacterial peritonitis and symptomatic bacterascites.
Gastroenterol Clin Biol.
2006;
30
446-452
MissingFormLabel
- 53
Nousbaum J B, Cadranel J F, Nahon P et al.
Diagnostic accuracy of the Multistix 8 SG reagent strip in diagnosis of spontaneous
bacterial peritonitis.
Hepatology.
2007;
45
1275-1281
MissingFormLabel
- 54
Nguyen-Khac E, Cadranel J F, Thevenot T et al.
Review article: the utility of reagent strips in the diagnosis of infected ascites
in cirrhotic patients.
Aliment Pharmacol Ther.
2008;
28
282-288
MissingFormLabel
- 55
Runyon B A, Hoefs J C, Morgan T R.
Ascitic fluid analysis in malignancy-related ascites.
Hepatology.
1988;
8
1104-1109
MissingFormLabel
- 56
Decker D, Stratmann H, Springer W et al.
Benign and malignant cells in effusions: diagnostic value of image DNA cytometry in
comparison to cytological analysis.
Pathol Res Pract.
1998;
194
791-795
MissingFormLabel
- 57
Jungst D, Gerbes A L, Martin R et al.
Value of ascitic lipids in the differentiation between cirrhotic and malignant ascites.
Hepatology.
1986;
6
239-243
MissingFormLabel
- 58
Gerbes A L, Xie Y N, Mezger J et al.
Ascitic fluid concentrations of fibronectin and cholesterol: comparison of differential
diagnostic value with the conventional protein determination.
Liver.
1990;
10
152-157
MissingFormLabel
- 59
Gerbes A L, Jungst D, Xie Y N et al.
Ascitic fluid analysis for the differentiation of malignancy-related and nonmalignant
ascites. Proposal of a diagnostic sequence.
Cancer.
1991;
68
1808-1814
MissingFormLabel
- 60
Gulyas M, Kaposi A D, Elek G et al.
Value of carcinoembryonic antigen (CEA) and cholesterol assays of ascitic fluid in
cases of inconclusive cytology.
J Clin Pathol.
2001;
54
831-835
MissingFormLabel
- 61
Boyer T D, Kahn A M, Reynolds T B.
Diagnostic value of ascitic fluid lactic dehydrogenase, protein, and WBC levels.
Arch Intern Med.
1978;
138
1103-1105
MissingFormLabel
- 62
Scholmerich J, Volk B A, Kottgen E et al.
Fibronectin concentration in ascites differentiates between malignant and nonmalignant
ascites.
Gastroenterology.
1984;
87
1160-1164
MissingFormLabel
- 63
Runyon B A.
Elevated ascitic fluid fibronectin concentration. A non-specific finding.
J Hepatol.
1986;
3
219-222
MissingFormLabel
- 64
Chen S J, Wang S S, Lu C W et al.
Clinical value of tumour markers and serum-ascites albumin gradient in the diagnosis
of malignancy-related ascites.
J Gastroenterol Hepatol.
1994;
9
396-400
MissingFormLabel
- 65
Khandwalla H E, Fasakin Y, El-Serag H B.
The utility of evaluating low serum albumin gradient ascites in patients with cirrhosis.
Am J Gastroenterol.
2009;
104
1401-1405
MissingFormLabel
- 66
Böcking A, Motherby H, Pomjanski N.
Treffsicherheit der Ergusszytologie samt adjuvanten Untersuchungsmethoden.
Dtsch Ärztebl.
2000;
97
A-2626
MissingFormLabel
- 67 Feichter G, Dalquen P. Zytopathologie. Berlin: Springer; 2000
MissingFormLabel
- 68
Motherby H, Nadjari B, Friegel P et al.
Diagnostic accuracy of effusion cytology.
Diagn Cytopathol.
1999;
20
350-357
MissingFormLabel
- 69 Rohn B L. Verbesserung der Treffsicherheit der Ergusszytologie mittels AgNOR-Analyse als adjuvante
Untersuchungsmethode. Düsseldorf: Institut für Cytopathologie. Medizinische Fakultät der Heinrich-Heine Universität; 2004: 45
MissingFormLabel
- 70
Moore K P, Aithal G P.
Guidelines on the management of ascites in cirrhosis.
Gut.
2006;
55 (Suppl 6)
vi1-12
MissingFormLabel
- 71 Böcking A. DNA measurements: When and why?. In: Wied G L, Keebler C M, Rosenthal D L, eds Compendium on quality assurance, proficiency testing, and workload limitations. Tutorials
of Cytology 1995.. Chicago IL; 1995: 170-188
MissingFormLabel
- 72
Schlake W, Kreipe H.
Mitteilungen Deutsche Gesellschaft für Pathologie. Erklärung zur Zytopathologie.
. Unter Mitarbeit von: A. Böcking, R. Bollmann, S. Falk, V. Fritzsche, A. Wellmann.
Pathologe.
2007;
28
393
MissingFormLabel
- 73 Spriggs A I, Boddington M M. The Cytology of Effusions in the Pleural, Pericardial and Peritoneal Cavities and
of Cerebrospinal Fluid. 2nd ed. London: Heinemann; 1968
MissingFormLabel
- 74
Giroud F, Haroske G, Reith A et al.
1997 ESACP consensus report on diagnostic DNA image cytometry. Part II: Specific recommendations
for quality assurance. European Society for Analytical Cellular Pathology.
Anal Cell Pathol.
1998;
17
201-208
MissingFormLabel
- 75
Haroske G, Giroud F, Reith A et al.
1997 ESACP consensus report on diagnostic DNA image cytometry. Part I: basic considerations
and recommendations for preparation, measurement and interpretation. European Society
for Analytical Cellular Pathology.
Anal Cell Pathol.
1998;
17
189-200
MissingFormLabel
- 76
Motherby H, Nadjari B, Remmerbach T et al.
Static DNA cytometry as a diagnostic aid in effusion cytology: II. DNA aneuploidy
for identification of neoplastic cells in equivocal effusions.
Anal Quant Cytol Histol.
1998;
20
162-168
MissingFormLabel
- 77
Pomjanski N, Motherby H, Buckstegge B et al.
Early diagnosis of mesothelioma in serous effusions using AgNOR analysis.
Anal Quant Cytol Histol.
2001;
23
151-160
MissingFormLabel
- 78
Darwish Murad S, Plessier A, Hernandez-Guerra M et al.
Etiology, management, and outcome of the Budd-Chiari syndrome.
Ann Intern Med.
2009;
151
167-175
MissingFormLabel
- 79
Valla D C.
Budd-Chiari syndrome and veno-occlusive disease/sinusoidal obstruction syndrome.
Gut.
2008;
57
1469-1478
MissingFormLabel
- 80
Darwish Murad S, Valla D C, Groen P C et al.
Determinants of survival and the effect of portosystemic shunting in patients with
Budd-Chiari syndrome.
Hepatology.
2004;
39
500-508
MissingFormLabel
- 81
Menon K V, Shah de V, Kamath P S.
The Budd-Chiari syndrome.
N Engl J Med.
2004;
350
578-585
MissingFormLabel
- 82
Ludwig J, Hashimoto E, McGill D B et al.
Classification of hepatic venous outflow obstruction: ambiguous terminology of the
Budd-Chiari syndrome.
Mayo Clin Proc.
1990;
65
51-55
MissingFormLabel
- 83
Okuda K, Kage M, Shrestha S M.
Proposal of a new nomenclature for Budd-Chiari syndrome: hepatic vein thrombosis versus
thrombosis of the inferior vena cava at its hepatic portion.
Hepatology.
1998;
28
1191-1198
MissingFormLabel
- 84
Hoekstra J, Leebeek F W, Plessier A et al.
Paroxysmal nocturnal hemoglobinuria in Budd-Chiari syndrome: findings from a cohort
study.
J Hepatol.
2009;
51
696-706
MissingFormLabel
- 85
Bolondi L, Gaiani S, Li Bassi S et al.
Diagnosis of Budd-Chiari syndrome by pulsed Doppler ultrasound.
Gastroenterology.
1991;
100
1324-1331
MissingFormLabel
- 86
Miller W J, Federle M P, Straub W H et al.
Budd-Chiari syndrome: imaging with pathologic correlation.
Abdom Imaging.
1993;
18
329-335
MissingFormLabel
- 87
Janssen H L, Garcia-Pagan J C, Elias E et al.
Budd-Chiari syndrome: a review by an expert panel.
J Hepatol.
2003;
38
364-371
MissingFormLabel
- 88
Valla D, Casadevall N, Lacombe C et al.
Primary myeloproliferative disorder and hepatic vein thrombosis. A prospective study
of erythroid colony formation in vitro in 20 patients with Budd-Chiari syndrome.
Ann Intern Med.
1985;
103
329-334
MissingFormLabel
- 89
Valla D.
Hepatic venous outflow tract obstruction etiopathogenesis: Asia versus the West.
J Gastroenterol Hepatol.
2004;
19
S204-S211
MissingFormLabel
- 90
Shulman H M, Fisher L B, Schoch H G et al.
Veno-occlusive disease of the liver after marrow transplantation: histological correlates
of clinical signs and symptoms.
Hepatology.
1994;
19
1171-1181
MissingFormLabel
- 91
Soriano G, Castellote J, Alvarez C et al.
Secondary bacterial peritonitis in cirrhosis: a retrospective study of clinical and
analytical characteristics, diagnosis and management.
J Hepatol.
2010;
52
39-44
MissingFormLabel
- 92
Caralis P V, Sprung C L, Schiff E R.
Secondary bacterial peritonitis in cirrhotic patients with ascites.
South Med J.
1984;
77
579-583
MissingFormLabel
- 93
Runyon B A, Hoefs J C.
Ascitic fluid analysis in the differentiation of spontaneous bacterial peritonitis
from gastrointestinal tract perforation into ascitic fluid.
Hepatology.
1984;
4
447-450
MissingFormLabel
- 94
Akriviadis E A, Runyon B A.
Utility of an algorithm in differentiating spontaneous from secondary bacterial peritonitis.
Gastroenterology.
1990;
98
127-133
MissingFormLabel
- 95
Garrison R N, Cryer H M, Howard D A et al.
Clarification of risk factors for abdominal operations in patients with hepatic cirrhosis.
Ann Surg.
1984;
199
648-655
MissingFormLabel
- 96
Wu S S, Lin O S, Chen Y Y et al.
Ascitic fluid carcinoembryonic antigen and alkaline phosphatase levels for the differentiation
of primary from secondary bacterial peritonitis with intestinal perforation.
J Hepatol.
2001;
34
215-221
MissingFormLabel
- 97
Mullen K D.
Review of the final report of the 1998 Working Party on definition, nomenclature and
diagnosis of hepatic encephalopathy.
Aliment Pharmacol Ther.
2007;
25 Suppl 1
11-16
MissingFormLabel
- 98
Moreau R, Lebrec D.
Diagnosis and treatment of acute renal failure in patients with cirrhosis.
Best Pract Res Clin Gastroenterol.
2007;
21
111-123
MissingFormLabel
- 99
D’Amico G, Morabito A, Pagliaro L et al.
Survival and prognostic indicators in compensated and decompensated cirrhosis.
Dig Dis Sci.
1986;
31
468-475
MissingFormLabel
- 100
Guardiola J, Baliellas C, Xiol X et al.
External validation of a prognostic model for predicting survival of cirrhotic patients
with refractory ascites.
Am J Gastroenterol.
2002;
97
2374-2378
MissingFormLabel
- 101
Planas R, Montoliu S, Balleste B et al.
Natural history of patients hospitalized for management of cirrhotic ascites.
Clin Gastroenterol Hepatol.
2006;
4
1385-1394
MissingFormLabel
- 102
Gines P, Cardenas A, Arroyo V et al.
Management of cirrhosis and ascites.
N Engl J Med.
2004;
350
1646-1654
MissingFormLabel
- 103
Llovet J M, Planas R, Morillas R et al.
Short-term prognosis of cirrhotics with spontaneous bacterial peritonitis: multivariate
study.
Am J Gastroenterol.
1993;
88
388-392
MissingFormLabel
- 104
Peng S, Plank L D, McCall J L et al.
Body composition, muscle function, and energy expenditure in patients with liver cirrhosis:
a comprehensive study.
Am J Clin Nutr.
2007;
85
1257-1266
MissingFormLabel
- 105
Prijatmoko D, Strauss B J, Lambert J R et al.
Early detection of protein depletion in alcoholic cirrhosis: role of body composition
analysis.
Gastroenterology.
1993;
105
1839-1845
MissingFormLabel
- 106
Cabre E, Gonzalez-Huix F, Abad-Lacruz A et al.
Effect of total enteral nutrition on the short-term outcome of severely malnourished
cirrhotics. A randomized controlled trial.
Gastroenterology.
1990;
98
715-720
MissingFormLabel
- 107
Kearns P J, Young H, Garcia G et al.
Accelerated improvement of alcoholic liver disease with enteral nutrition.
Gastroenterology.
1992;
102
200-205
MissingFormLabel
- 108
Caregaro L, Alberino F, Amodio P et al.
Malnutrition in alcoholic and virus-related cirrhosis.
Am J Clin Nutr.
1996;
63
602-609
MissingFormLabel
- 109
Selberg O, Bottcher J, Tusch G et al.
Identification of high- and low-risk patients before liver transplantation: a prospective
cohort study of nutritional and metabolic parameters in 150 patients.
Hepatology.
1997;
25
652-657
MissingFormLabel
- 110
Pirlich M, Schutz T, Spachos T et al.
Bioelectrical impedance analysis is a useful bedside technique to assess malnutrition
in cirrhotic patients with and without ascites.
Hepatology.
2000;
32
1208-1215
MissingFormLabel
- 111
Selberg O, Selberg D.
Norms and correlates of bioimpedance phase angle in healthy human subjects, hospitalized
patients, and patients with liver cirrhosis.
Eur J Appl Physiol.
2002;
86
509-516
MissingFormLabel
- 112
Plauth M, Cabre E, Riggio O et al.
ESPEN Guidelines on Enteral Nutrition: Liver disease.
Clin Nutr.
2006;
25
285-294
MissingFormLabel
- 113
Plauth M, Cabre E, Campillo B et al.
ESPEN Guidelines on Parenteral Nutrition: hepatology.
Clin Nutr.
2009;
28
436-444
MissingFormLabel
- 114
Plauth M, Schutz T, Buckendahl D P et al.
Weight gain after transjugular intrahepatic portosystemic shunt is associated with
improvement in body composition in malnourished patients with cirrhosis and hypermetabolism.
J Hepatol.
2004;
40
228-233
MissingFormLabel
- 115
Plank L D, Gane E J, Peng S et al.
Nocturnal nutritional supplementation improves total body protein status of patients
with liver cirrhosis: a randomized 12-month trial.
Hepatology.
2008;
48
557-566
MissingFormLabel
- 116
Zillikens M C, Berg J W, Wattimena J L et al.
Nocturnal oral glucose supplementation. The effects on protein metabolism in cirrhotic
patients and in healthy controls.
J Hepatol.
1993;
17
377-383
MissingFormLabel
- 117
Cordoba van den J, Lopez-Hellin J, Planas M et al.
Normal protein diet for episodic hepatic encephalopathy: results of a randomized study.
J Hepatol.
2004;
41
38-43
MissingFormLabel
- 118
Madden A M, Bradbury W, Morgan M Y.
Taste perception in cirrhosis: its relationship to circulating micronutrients and
food preferences.
Hepatology.
1997;
26
40-48
MissingFormLabel
- 119
Soulsby C T, Madden A M, Morgan M Y.
The effect of dietary sodium restriction on energy and protein intake in patients
with cirrhosis (Abstract).
Hepatology.
1997;
26
382A
MissingFormLabel
- 120
Chobanian A V, Bakris G L, Black H R et al.
Seventh report of the Joint National Committee on Prevention, Detection, Evaluation,
and Treatment of High Blood Pressure.
Hypertension.
2003;
42
1206-1252
MissingFormLabel
- 121
Mancia G, De Backer G, Dominiczak A et al.
2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the
Management of Arterial Hypertension of the European Society of Hypertension (ESH)
and of the European Society of Cardiology (ESC).
J Hypertens.
2007;
25
1105-1187
MissingFormLabel
- 122
Reynolds T B, Lieberman F L, Goodman A R.
Advantages of treatment of ascites without sodium restriction and without complete
removal of excess fluid.
Gut.
1978;
19
549-553
MissingFormLabel
- 123
Gauthier A, Levy V G, Quinton A et al.
Salt or no salt in the treatment of cirrhotic ascites: a randomised study.
Gut.
1986;
27
705-709
MissingFormLabel
- 124
Bernardi M, Laffi G, Salvagnini M et al.
Efficacy and safety of the stepped care medical treatment of ascites in liver cirrhosis:
a randomized controlled clinical trial comparing two diets with different sodium content.
Liver.
1993;
13
156-162
MissingFormLabel
- 125
Ring-Larsen H, Henriksen J H, Wilken C et al.
Diuretic treatment in decompensated cirrhosis and congestive heart failure: effect
of posture.
Br Med J (Clin Res Ed).
1986;
292
1351-1353
MissingFormLabel
- 126
Angeli P, Wong F, Watson H et al.
Hyponatremia in cirrhosis: Results of a patient population survey.
Hepatology.
2006;
44
1535-1542
MissingFormLabel
- 127
Biggins S W, Kim W R, Terrault N A et al.
Evidence-based incorporation of serum sodium concentration into MELD.
Gastroenterology.
2006;
130
1652-1660
MissingFormLabel
- 128
Hecker R, Sherlock S.
Electrolyte and circulatory changes in terminal liver failure.
Lancet.
1956;
271
1121-1125
MissingFormLabel
- 129
Kim W R, Biggins S W, Kremers W K et al.
Hyponatremia and mortality among patients on the liver-transplant waiting list.
N Engl J Med.
2008;
359
1018-1026
MissingFormLabel
- 130
Abbasoglu O, Goldstein R M, Vodapally M S et al.
Liver transplantation in hyponatremic patients with emphasis on central pontine myelinolysis.
Clin Transplant.
1998;
12
263-269
MissingFormLabel
- 131
Sterns R H.
Severe symptomatic hyponatremia: treatment and outcome. A study of 64 cases.
Ann Intern Med.
1987;
107
656-664
MissingFormLabel
- 132
Runyon B A.
Management of adult patients with ascites due to cirrhosis: an update.
Hepatology.
2009;
49
2087-2107
MissingFormLabel
- 133
Descos L, Gauthier A, Levy V G et al.
Comparison of six treatments of ascites in patients with liver cirrhosis. A clinical
trial.
Hepatogastroenterology.
1983;
30
15-20
MissingFormLabel
- 134
Fogel M R, Sawhney V K, Neal E A et al.
Diuresis in the ascitic patient: a randomized controlled trial of three regimens.
J Clin Gastroenterol.
1981;
3 (Suppl 1)
73-80
MissingFormLabel
- 135
Perez-Ayuso R M, Arroyo V, Planas R et al.
Randomized comparative study of efficacy of furosemide versus spironolactone in nonazotemic
cirrhosis with ascites. Relationship between the diuretic response and the activity
of the renin-aldosterone system.
Gastroenterology.
1983;
84
961-968
MissingFormLabel
- 136
Santos J, Planas R, Pardo A et al.
Spironolactone alone or in combination with furosemide in the treatment of moderate
ascites in nonazotemic cirrhosis. A randomized comparative study of efficacy and safety.
J Hepatol.
2003;
39
187-192
MissingFormLabel
- 137
Pockros P J, Reynolds T B.
Rapid diuresis in patients with ascites from chronic liver disease: the importance
of peripheral edema.
Gastroenterology.
1986;
90
1827-1833
MissingFormLabel
- 138
Bernardi M, Servadei D, Trevisani F et al.
Importance of plasma aldosterone concentration on the natriuretic effect of spironolactone
in patients with liver cirrhosis and ascites.
Digestion.
1985;
31
189-193
MissingFormLabel
- 139
Gatta A, Angeli P, Caregaro L et al.
A pathophysiological interpretation of unresponsiveness to spironolactone in a stepped-care
approach to the diuretic treatment of ascites in nonazotemic cirrhotic patients.
Hepatology.
1991;
14
231-236
MissingFormLabel
- 140
Angeli P, Fasolato S, Mazza E et al.
Combined versus sequential diuretic treatment of ascites in non-azotaemic patients
with cirrhosis: results of an open randomised clinical trial.
Gut.
2010;
59
98-104
MissingFormLabel
- 141
Daskalopoulos G, Laffi G, Morgan T et al.
Immediate effects of furosemide on renal hemodynamics in chronic liver disease with
ascites.
Gastroenterology.
1987;
92
1859-1863
MissingFormLabel
- 142
Sawhney V K, Gregory P B, Swezey S E et al.
Furosemide disposition in cirrhotic patients.
Gastroenterology.
1981;
81
1012-1016
MissingFormLabel
- 143
Stanley M M, Ochi S, Lee K K et al.
Peritoneovenous shunting as compared with medical treatment in patients with alcoholic
cirrhosis and massive ascites. Veterans Administration Cooperative Study on Treatment
of Alcoholic Cirrhosis with Ascites.
N Engl J Med.
1989;
321
1632-1638
MissingFormLabel
- 144
Runyon B A.
Care of patients with ascites.
N Engl J Med.
1994;
330
337-342
MissingFormLabel
- 145
Abecasis R, Guevara M, Miguez C et al.
Long-term efficacy of torasemide compared with frusemide in cirrhotic patients with
ascites.
Scand J Gastroenterol.
2001;
36
309-313
MissingFormLabel
- 146
Fiaccadori F, Pedretti G, Pasetti G et al.
Torasemide versus furosemide in cirrhosis: a long-term, double-blind, randomized clinical
study.
Clin Investig.
1993;
71
579-584
MissingFormLabel
- 147
Gerbes A L, Bertheau-Reith U, Falkner C et al.
Advantages of the new loop diuretic torasemide over furosemide in patients with cirrhosis
and ascites. A randomized, double blind cross-over trial.
J Hepatol.
1993;
17
353-358
MissingFormLabel
- 148
Angeli P, Dalla Pria M, De Bei E et al.
Randomized clinical study of the efficacy of amiloride and potassium canrenoate in
nonazotemic cirrhotic patients with ascites.
Hepatology.
1994;
19
72-79
MissingFormLabel
- 149
Ginsberg D J, Saad A, Gabuzda G J.
Metabolic Studies with the Diuretic Triamterene in Patients with Cirrhosis and Ascites.
N Engl J Med.
1964;
271
1229-1235
MissingFormLabel
- 150
Knauf H, Mutschler E.
Liver cirrhosis with ascites: pathogenesis of resistance to diuretics and long-term
efficacy and safety of torasemide.
Cardiology.
1994;
84 (Suppl 2)
87-98
MissingFormLabel
- 151
McHutchison J G, Pinto P C, Reynolds T B.
Hydrochlorothiazide as a third diuretic in cirrhosis with refractory ascites (Abstract).
Hepatology.
1989;
10
719
MissingFormLabel
- 152
Pitt B, Remme W, Zannad F et al.
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction
after myocardial infarction.
N Engl J Med.
2003;
348
1309-1321
MissingFormLabel
- 153
Gines P, Wong F, Watson H et al.
Effects of satavaptan, a selective vasopressin V(2) receptor antagonist, on ascites
and serum sodium in cirrhosis with hyponatremia: a randomized trial.
Hepatology.
2008;
48
204-213
MissingFormLabel
- 154
Rosemurgy A S, Zervos E E, Clark W C et al.
TIPS versus peritoneovenous shunt in the treatment of medically intractable ascites:
a prospective randomized trial.
Ann Surg.
2004;
239
883-889
; discussion 889 – 891
MissingFormLabel
- 155
Gines A, Fernandez-Esparrach G, Monescillo A et al.
Randomized trial comparing albumin, dextran 70, and polygeline in cirrhotic patients
with ascites treated by paracentesis.
Gastroenterology.
1996;
111
1002-1010
MissingFormLabel
- 156
Gines P, Tito L, Arroyo V et al.
Randomized comparative study of therapeutic paracentesis with and without intravenous
albumin in cirrhosis.
Gastroenterology.
1988;
94
1493-1502
MissingFormLabel
- 157
Pozzi M, Osculati G, Boari G et al.
Time course of circulatory and humoral effects of rapid total paracentesis in cirrhotic
patients with tense, refractory ascites.
Gastroenterology.
1994;
106
709-719
MissingFormLabel
- 158
Lebrec D, Giuily N, Hadengue A et al.
Transjugular intrahepatic portosystemic shunts: comparison with paracentesis in patients
with cirrhosis and refractory ascites: a randomized trial. French Group of Clinicians
and a Group of Biologists.
J Hepatol.
1996;
25
135-144
MissingFormLabel
- 159
Wong F, Sniderman K, Liu P et al.
Transjugular intrahepatic portosystemic stent shunt: effects on hemodynamics and sodium
homeostasis in cirrhosis and refractory ascites.
Ann Intern Med.
1995;
122
816-822
MissingFormLabel
- 160
Gines P, Uriz J, Calahorra B et al.
Transjugular intrahepatic portosystemic shunting versus paracentesis plus albumin
for refractory ascites in cirrhosis.
Gastroenterology.
2002;
123
1839-1847
MissingFormLabel
- 161
Rossle M, Ochs A, Gulberg V et al.
A comparison of paracentesis and transjugular intrahepatic portosystemic shunting
in patients with ascites.
N Engl J Med.
2000;
342
1701-1707
MissingFormLabel
- 162
Salerno F, Camma C, Enea M et al.
Transjugular intrahepatic portosystemic shunt for refractory ascites: a meta-analysis
of individual patient data.
Gastroenterology.
2007;
133
825-834
MissingFormLabel
- 163
Sanyal A J, Genning C, Reddy K R et al.
The North American Study for the Treatment of Refractory Ascites.
Gastroenterology.
2003;
124
634-641
MissingFormLabel
- 164
Salerno F, Merli M, Riggio O et al.
Randomized controlled study of TIPS versus paracentesis plus albumin in cirrhosis
with severe ascites.
Hepatology.
2004;
40
629-635
MissingFormLabel
- 165
Gulberg V, Liss I, Bilzer M et al.
Improved quality of life in patients with refractory or recidivant ascites after insertion
of transjugular intrahepatic portosystemic shunts.
Digestion.
2002;
66
127-130
MissingFormLabel
- 166
Bureau C, Garcia-Pagan J C, Otal P et al.
Improved clinical outcome using polytetrafluoroethylene-coated stents for TIPS: results
of a randomized study.
Gastroenterology.
2004;
126
469-475
MissingFormLabel
- 167
Albillos A, Banares R, Gonzalez M et al.
A meta-analysis of transjugular intrahepatic portosystemic shunt versus paracentesis
for refractory ascites.
J Hepatol.
2005;
43
990-996
MissingFormLabel
- 168
D’Amico G, Luca A, Morabito A et al.
Uncovered transjugular intrahepatic portosystemic shunt for refractory ascites: a
meta-analysis.
Gastroenterology.
2005;
129
1282-1293
MissingFormLabel
- 169
Deltenre P, Mathurin P, Dharancy S et al.
Transjugular intrahepatic portosystemic shunt in refractory ascites: a meta-analysis.
Liver Int.
2005;
25
349-356
MissingFormLabel
- 170
Riggio O, Ridola L, Angeloni S et al.
Clinical efficacy of transjugular intrahepatic portosystemic shunt created with covered
stents with different diameters: results of a randomized controlled trial.
J Hepatol.
2010;
53
267-272
MissingFormLabel
- 171
Rossle M, Mullen K D.
Long-term patency is expected with covered TIPS stents: this effect may not always
be desirable!.
Hepatology.
2004;
40
495-497
MissingFormLabel
- 172
Rossle M, Gerbes A L.
TIPS for the treatment of refractory ascites, hepatorenal syndrome and hepatic hydrothorax:
a critical update.
Gut.
2010;
59
988-1000
MissingFormLabel
- 173
Chalasani N, Clark W S, Martin L G et al.
Determinants of mortality in patients with advanced cirrhosis after transjugular intrahepatic
portosystemic shunting.
Gastroenterology.
2000;
118
138-144
MissingFormLabel
- 174
Rajan D K, Haskal Z J, Clark T W.
Serum bilirubin and early mortality after transjugular intrahepatic portosystemic
shunts: results of a multivariate analysis.
J Vasc Interv Radiol.
2002;
13
155-161
MissingFormLabel
- 175
Gerbes A L, Gulberg V.
Benefit of TIPS for patients with refractory or recidivant ascites: serum bilirubin
may make the difference.
Hepatology.
2005;
41
217
MissingFormLabel
- 176
Cazzaniga M, Salerno F, Pagnozzi G et al.
Diastolic dysfunction is associated with poor survival in patients with cirrhosis
with transjugular intrahepatic portosystemic shunt.
Gut.
2007;
56
869-875
MissingFormLabel
- 177
Runyon B A.
Monomicrobial nonneutrocytic bacterascites: a variant of spontaneous bacterial peritonitis.
Hepatology.
1990;
12
710-715
MissingFormLabel
- 178
Fernandez J, Navasa M, Gomez J et al.
Bacterial infections in cirrhosis: epidemiological changes with invasive procedures
and norfloxacin prophylaxis.
Hepatology.
2002;
35
140-148
MissingFormLabel
- 179
Castellote J, Girbau A, Maisterra S et al.
Spontaneous bacterial peritonitis and bacterascites prevalence in asymptomatic cirrhotic
outpatients undergoing large-volume paracentesis.
J Gastroenterol Hepatol.
2008;
23
256-259
MissingFormLabel
- 180
Conn H O, Fessel J M.
Spontaneous bacterial peritonitis in cirrhosis: variations on a theme.
Medicine.
1971;
50
161-197
MissingFormLabel
- 181
Gines P, Rimola A, Planas R et al.
Norfloxacin prevents spontaneous bacterial peritonitis recurrence in cirrhosis: results
of a double-blind, placebo-controlled trial.
Hepatology.
1990;
12
716-724
MissingFormLabel
- 182
Tito L, Rimola A, Gines P et al.
Recurrence of spontaneous bacterial peritonitis in cirrhosis: frequency and predictive
factors.
Hepatology.
1988;
8
27-31
MissingFormLabel
- 183
Hsieh W J, Lin H C, Hwang S J et al.
The effect of ciprofloxacin in the prevention of bacterial infection in patients with
cirrhosis after upper gastrointestinal bleeding.
Am J Gastroenterol.
1998;
93
962-966
MissingFormLabel
- 184
Pauwels A, Mostefa-Kara N, Debenes B et al.
Systemic antibiotic prophylaxis after gastrointestinal hemorrhage in cirrhotic patients
with a high risk of infection.
Hepatology.
1996;
24
802-806
MissingFormLabel
- 185
Rolachon A, Cordier L, Bacq Y et al.
Ciprofloxacin and long-term prevention of spontaneous bacterial peritonitis: results
of a prospective controlled trial.
Hepatology.
1995;
22
1171-1174
MissingFormLabel
- 186
Soriano G, Guarner C, Teixido M et al.
Selective intestinal decontamination prevents spontaneous bacterial peritonitis.
Gastroenterology.
1991;
100
477-481
MissingFormLabel
- 187
Terg R, Fassio E, Guevara M et al.
Ciprofloxacin in primary prophylaxis of spontaneous bacterial peritonitis: a randomized,
placebo-controlled study.
J Hepatol.
2008;
48
774-779
MissingFormLabel
- 188
Obstein K L, Campbell M S, Reddy K R et al.
Association between model for end-stage liver disease and spontaneous bacterial peritonitis.
Am J Gastroenterol.
2007;
102
2732-2736
MissingFormLabel
- 189
Bajaj J S, Zadvornova Y, Heuman D M et al.
Association of proton pump inhibitor therapy with spontaneous bacterial peritonitis
in cirrhotic patients with ascites.
Am J Gastroenterol.
2009;
104
1130-1134
MissingFormLabel
- 190
Appenrodt B, Grunhage F, Gentemann M G et al.
Nucleotide-binding oligomerization domain containing 2 (NOD2) variants are genetic
risk factors for death and spontaneous bacterial peritonitis in liver cirrhosis.
Hepatology.
2010;
51
1327-1333
MissingFormLabel
- 191
Chu C M, Chang K Y, Liaw Y F.
Prevalence and prognostic significance of bacterascites in cirrhosis with ascites.
Dig Dis Sci.
1995;
40
561-565
MissingFormLabel
- 192
Follo A, Llovet J M, Navasa M et al.
Renal impairment after spontaneous bacterial peritonitis in cirrhosis: incidence,
clinical course, predictive factors and prognosis.
Hepatology.
1994;
20
1495-1501
MissingFormLabel
- 193
Nobre S R, Cabral J E, Gomes J J et al.
In-hospital mortality in spontaneous bacterial peritonitis: a new predictive model.
Eur J Gastroenterol Hepatol.
2008;
20
1176-1181
MissingFormLabel
- 194
Pinzello G, Simonetti R G, Craxi A et al.
Spontaneous bacterial peritonitis: a prospective investigation in predominantly nonalcoholic
cirrhotic patients.
Hepatology.
1983;
3
545-549
MissingFormLabel
- 195
Thuluvath P J, Morss S, Thompson R.
Spontaneous bacterial peritonitis--in-hospital mortality, predictors of survival,
and health care costs from 1988 to 1998.
Am J Gastroenterol.
2001;
96
1232-1236
MissingFormLabel
- 196
Toledo C, Salmeron J M, Rimola A et al.
Spontaneous bacterial peritonitis in cirrhosis: predictive factors of infection resolution
and survival in patients treated with cefotaxime.
Hepatology.
1993;
17
251-257
MissingFormLabel
- 197
Andreu M, Sola R, Sitges-Serra A et al.
Risk factors for spontaneous bacterial peritonitis in cirrhotic patients with ascites.
Gastroenterology.
1993;
104
1133-1138
MissingFormLabel
- 198
Silvain C, Besson I, Ingrand P et al.
Prognosis and long-term recurrence of spontaneous bacterial peritonitis in cirrhosis.
J Hepatol.
1993;
19
188-189
MissingFormLabel
- 199
Terg R, Levi D, Lopez P et al.
Analysis of clinical course and prognosis of culture-positive spontaneous bacterial
peritonitis and neutrocytic ascites. Evidence of the same disease.
Dig Dis Sci.
1992;
37
1499-1504
MissingFormLabel
- 200
Altman C, Grange J D, Amiot X et al.
Survival after a first episode of spontaneous bacterial peritonitis. Prognosis of
potential candidates for orthotopic liver transplantation.
J Gastroenterol Hepatol.
1995;
10
47-50
MissingFormLabel
- 201
Almdal T P, Skinhoj P.
Spontaneous bacterial peritonitis in cirrhosis. Incidence, diagnosis, and prognosis.
Scand J Gastroenterol.
1987;
22
295-300
MissingFormLabel
- 202
Weinstein M P, Iannini P B, Stratton C W et al.
Spontaneous bacterial peritonitis. A review of 28 cases with emphasis on improved
survival and factors influencing prognosis.
Am J Med.
1978;
64
592-598
MissingFormLabel
- 203
Terg R, Gadano A, Cartier M et al.
Serum creatinine and bilirubin predict renal failure and mortality in patients with
spontaneous bacterial peritonitis: a retrospective study.
Liver Int.
2009;
29
415-419
MissingFormLabel
- 204
Franca A V, De Souza J B, Silva C M et al.
Long-term prognosis of cirrhosis after spontaneous bacterial peritonitis treated with
ceftriaxone.
J Clin Gastroenterol.
2001;
33
295-298
MissingFormLabel
- 205
Kamani L, Mumtaz K, Ahmed U S et al.
Outcomes in culture positive and culture negative ascitic fluid infection in patients
with viral cirrhosis: cohort study.
BMC Gastroenterol.
2008;
8
59
MissingFormLabel
- 206
Cho J H, Park K H, Kim S H et al.
Bacteremia is a prognostic factor for poor outcome in spontaneous bacterial peritonitis.
Scand J Infect Dis.
2007;
39
697-702
MissingFormLabel
- 207
Alvarez R F, Mattos A A, Correa E B et al.
Trimethoprim-sulfamethoxazole versus norfloxacin in the prophylaxis of spontaneous
bacterial peritonitis in cirrhosis.
Arq Gastroenterol.
2005;
42
256-262
MissingFormLabel
- 208
Singh N, Gayowski T, Yu V L et al.
Trimethoprim-sulfamethoxazole for the prevention of spontaneous bacterial peritonitis
in cirrhosis: a randomized trial.
Ann Intern Med.
1995;
122
595-598
MissingFormLabel
- 209
Novella M, Sola R, Soriano G et al.
Continuous versus inpatient prophylaxis of the first episode of spontaneous bacterial
peritonitis with norfloxacin.
Hepatology.
1997;
25
532-536
MissingFormLabel
- 210
Fernandez J, Navasa M, Planas R et al.
Primary prophylaxis of spontaneous bacterial peritonitis delays hepatorenal syndrome
and improves survival in cirrhosis.
Gastroenterology.
2007;
133
818-824
MissingFormLabel
- 211
Grange J D, Roulot D, Pelletier G et al.
Norfloxacin primary prophylaxis of bacterial infections in cirrhotic patients with
ascites: a double-blind randomized trial.
J Hepatol.
1998;
29
430-436
MissingFormLabel
- 212
Loomba R, Wesley R, Bain A et al.
Role of fluoroquinolones in the primary prophylaxis of spontaneous bacterial peritonitis:
meta-analysis.
Clin Gastroenterol Hepatol.
2009;
7
487-493
MissingFormLabel
- 213
Saab S, Hernandez J C, Chi A C et al.
Oral antibiotic prophylaxis reduces spontaneous bacterial peritonitis occurrence and
improves short-term survival in cirrhosis: a meta-analysis.
Am J Gastroenterol.
2009;
104
993-1001
; quiz 1002
MissingFormLabel
- 214
Krag A, Wiest R, Gluud L L.
Fluoroquinolones in the primary prophylaxis of spontaneous bacterial peritonitis.
Am J Gastroenterol.
2010;
105
1444
; author reply 1444 – 1445
MissingFormLabel
- 215
Lo R, Austin A S, Freeman J G.
Antibiotic prophylaxis for the primary prevention of spontaneous bacterial peritonitis
in cirrhotic patients with low ascitic protein: A meta-analysis.
J Hepatol.
2009;
50
S82
MissingFormLabel
- 216
Ortiz J, Vila M C, Soriano G et al.
Infections caused by Escherichia coli resistant to norfloxacin in hospitalized cirrhotic
patients.
Hepatology.
1999;
29
1064-1069
MissingFormLabel
- 217
Bajaj J S, Ananthakrishnan A N, Hafeezullah M et al.
Clostridium difficile is associated with poor outcomes in patients with cirrhosis:
A national and tertiary center perspective.
Am J Gastroenterol.
2010;
105
106-113
MissingFormLabel
- 218
Runyon B A.
A pill a day can improve survival in patients with advanced cirrhosis.
Gastroenterology.
2007;
133
1029-1031
MissingFormLabel
- 219
Wade J J, Rolando N, Hayllar K et al.
Bacterial and fungal infections after liver transplantation: an analysis of 284 patients.
Hepatology.
1995;
21
1328-1336
MissingFormLabel
- 220
Lontos S, Gow P J, Vaughan R B et al.
Norfloxacin and trimethoprim-sulfamethoxazole therapy have similar efficacy in prevention
of spontaneous bacterial peritonitis.
J Gastroenterol Hepatol.
2008;
23
252-255
MissingFormLabel
- 221
Terg R, Llano K, Cobas S M et al.
Effects of oral ciprofloxacin on aerobic gram-negative fecal flora in patients with
cirrhosis: results of short- and long-term administration, with daily and weekly dosages.
J Hepatol.
1998;
29
437-442
MissingFormLabel
- 222
Goulis J, Patch D, Burroughs A K.
Bacterial infection in the pathogenesis of variceal bleeding.
Lancet.
1999;
353
139-142
MissingFormLabel
- 223
Bernard B, Cadranel J F, Valla D et al.
Prognostic significance of bacterial infection in bleeding cirrhotic patients: a prospective
study.
Gastroenterology.
1995;
108
1828-1834
MissingFormLabel
- 224
Goulis J, Armonis A, Patch D et al.
Bacterial infection is independently associated with failure to control bleeding in
cirrhotic patients with gastrointestinal hemorrhage.
Hepatology.
1998;
27
1207-1212
MissingFormLabel
- 225
Bernard B, Grange J D, Khac E N et al.
Antibiotic prophylaxis for the prevention of bacterial infections in cirrhotic patients
with gastrointestinal bleeding: a meta-analysis.
Hepatology.
1999;
29
1655-1661
MissingFormLabel
- 226
Chaves-Tapia N C, Barrientos-Gutierres T, Tellez-Avila F I et al.
Antibiotic prophylaxis for cirrhotic patients with upper gastrointestinal bleeding.
Cochrane Database Syst Rev.
2010 Sep 8;
(9)
CD002907
MissingFormLabel
- 227
Franchis de R.
Evolving consensus in portal hypertension. Report of the Baveno IV consensus workshop
on methodology of diagnosis and therapy in portal hypertension.
J Hepatol.
2005;
43
167-176
MissingFormLabel
- 228
Tuncer I, Topcu N, Durmus A et al.
Oral ciprofloxacin versus intravenous cefotaxime and ceftriaxone in the treatment
of spontaneous bacterial peritonitis.
Hepatogastroenterology.
2003;
50
1426-1430
MissingFormLabel
- 229
Navasa M, Follo A, Llovet J M et al.
Randomized, comparative study of oral ofloxacin versus intravenous cefotaxime in spontaneous
bacterial peritonitis.
Gastroenterology.
1996;
111
1011-1017
MissingFormLabel
- 230
Angeli P, Guarda S, Fasolato S et al.
Switch therapy with ciprofloxacin vs. intravenous ceftazidime in the treatment of
spontaneous bacterial peritonitis in patients with cirrhosis: similar efficacy at
lower cost.
Aliment Pharmacol Ther.
2006;
23
75-84
MissingFormLabel
- 231
Taskiran B, Colakoglu O, Sozmen B et al.
Comparison of cefotaxime and ofloxacin in treatment of spontaneous bacterial peritonitis.
Turk J Gastroenterol.
2004;
15
34-38
MissingFormLabel
- 232
Terg R, Cobas S, Fassio E et al.
Oral ciprofloxacin after a short course of intravenous ciprofloxacin in the treatment
of spontaneous bacterial peritonitis: results of a multicenter, randomized study.
J Hepatol.
2000;
33
564-569
MissingFormLabel
- 233
Park Y H, Lee H C, Song H G et al.
Recent increase in antibiotic-resistant microorganisms in patients with spontaneous
bacterial peritonitis adversely affects the clinical outcome in Korea.
J Gastroenterol Hepatol.
2003;
18
927-933
MissingFormLabel
- 234
Singh N, Wagener M M, Gayowski T.
Changing epidemiology and predictors of mortality in patients with spontaneous bacterial
peritonitis at a liver transplant unit.
Clin Microbiol Infect.
2003;
9
531-537
MissingFormLabel
- 235 Kresken M, Hafner D, Schmitz F J et al. PEG-Resistenzstudie: Resistenzsituation bei klinisch wichtigen Infektionserregern
gegenüber Antibiotika in Deutschland und im mitteleuropäischen Raum. Paul-Ehrlich-Gesellschaft für Chemotherapie e.V; 2007
MissingFormLabel
- 236 Kresken M, Hafner D, Schmitz F J et al. PEG-Resistenzstudie: Daten zur Resistenzlage bei klinisch wichtigen Bakterienspezies
gegenüber Antibiotika in Mitteleuropa. Paul-Ehrlich-Gesellschaft für Chemotherapie e.V; 2010
MissingFormLabel
- 237
Felisart J, Rimola A, Arroyo V et al.
Cefotaxime is more effective than is ampicillin-tobramycin in cirrhotics with severe
infections.
Hepatology.
1985;
5
457-462
MissingFormLabel
- 238
Rimola A, Salmeron J M, Clemente G et al.
Two different dosages of cefotaxime in the treatment of spontaneous bacterial peritonitis
in cirrhosis: results of a prospective, randomized, multicenter study.
Hepatology.
1995;
21
674-679
MissingFormLabel
- 239
Rimola A, Navasa M, Arroyo V.
Experience with cefotaxime in the treatment of spontaneous bacterial peritonitis in
cirrhosis.
Diagn Microbiol Infect Dis.
1995;
22
141-145
MissingFormLabel
- 240
Gomez-Jimenez J, Ribera E, Gasser I et al.
Randomized trial comparing ceftriaxone with cefonicid for treatment of spontaneous
bacterial peritonitis in cirrhotic patients.
Antimicrob Agents Chemother.
1993;
37
1587-1592
MissingFormLabel
- 241
Ricart E, Soriano G, Novella M T et al.
Amoxicillin-clavulanic acid versus cefotaxime in the therapy of bacterial infections
in cirrhotic patients.
J Hepatol.
2000;
32
596-602
MissingFormLabel
- 242
Acevedo J C, Fernandez J, Castro M et al.
Current efficacy of recommended empirical antibiotic therapy in patients with cirrhosis
and bacterial infection (Abstract).
J Hepatol.
2009;
50
S5
MissingFormLabel
- 243
Castellote J, Ariza X, Girbau A et al.
Risk factors to cefotaxime-resistant spontaneous bacterial peritonitis (Abstract).
J Hepatol.
2010;
52
S69
MissingFormLabel
- 244
Angeloni S, Leboffe C, Parente A et al.
Efficacy of current guidelines for the treatment of spontaneous bacterial peritonitis
in the clinical practice.
World J Gastroenterol.
2008;
14
2757-2762
MissingFormLabel
- 245
Yakar T, Guclu M, Serin E et al.
A recent evaluation of empirical cephalosporin treatment and antibiotic resistance
of changing bacterial profiles in spontaneous bacterial peritonitis.
Dig Dis Sci.
2010;
55
1149-1154
MissingFormLabel
- 246
Castellote J, Ariza X, Girbau A et al.
Antibiotic-resistant bacteria in spontaneous bacterial peritonitis. Is it time to
change? (Abstract).
J Hepatol.
2010;
52
S69
MissingFormLabel
- 247
Cheong H S, Kang C I, Lee J A et al.
Clinical significance and outcome of nosocomial acquisition of spontaneous bacterial
peritonitis in patients with liver cirrhosis.
Clin Infect Dis.
2009;
48
1230-1236
MissingFormLabel
- 248
Dupeyron C, Mangeney N, Sedrati L et al.
Rapid emergence of quinolone resistance in cirrhotic patients treated with norfloxacin
to prevent spontaneous bacterial peritonitis.
Antimicrob Agents Chemother.
1994;
38
340-344
MissingFormLabel
- 249
Dupeyron C, Campillo S B, Mangeney N et al.
Carriage of Staphylococcus aureus and of gram-negative bacilli resistant to third-generation
cephalosporins in cirrhotic patients: a prospective assessment of hospital-acquired
infections.
Infect Control Hosp Epidemiol.
2001;
22
427-432
MissingFormLabel
- 250
Campillo B, Dupeyron C, Richardet J P et al.
Epidemiology of severe hospital-acquired infections in patients with liver cirrhosis:
effect of long-term administration of norfloxacin.
Clin Infect Dis.
1998;
26
1066-1070
MissingFormLabel
- 251
Campillo B, Dupeyron C, Richardet J P.
Epidemiology of hospital-acquired infections in cirrhotic patients: effect of carriage
of methicillin-resistant Staphylococcus aureus and influence of previous antibiotic
therapy and norfloxacin prophylaxis.
Epidemiol Infect.
2001;
127
443-450
MissingFormLabel
- 252
Song K H, Jeon J H, Park W B et al.
Clinical outcomes of spontaneous bacterial peritonitis due to extended-spectrum beta-lactamase-producing
Escherichia coli and Klebsiella species: a retrospective matched case-control study.
BMC Infect Dis.
2009;
9
41
MissingFormLabel
- 253
Umgelter A, Reindl W, Miedaner M et al.
Failure of current antibiotic first-line regimens and mortality in hospitalized patients
with spontaneous bacterial peritonitis.
Infection.
2009;
37
2-8
MissingFormLabel
- 254
Chavez-Tapia N C, Soares-Weiser K, Brezis M et al.
Antibiotics for spontaneous bacterial peritonitis in cirrhotic patients.
Cochrane Database Syst Rev.
2009;
CD002232
MissingFormLabel
- 255
Chen T A, Lo G H, Lai K H et al.
Single daily amikacin versus cefotaxime in the short-course treatment of spontaneous
bacterial peritonitis in cirrhotics.
World J Gastroenterol.
2005;
11
6823-6827
MissingFormLabel
- 256
Rastegar L A, Umrani G, Dehbashi N et al.
Evaluation of the therapeutic effect of pefloxacin in comparison with ampicillin and
gentamicin in cirrhotic patients with spontaneous bacterial peritonitis.
Hepatogastroenterology.
1998;
45
783-785
MissingFormLabel
- 257
Antillon M R, Runyon B A.
Effect of marked peripheral leukocytosis on the leukocyte count in ascites.
Arch Intern Med.
1991;
151
509-510
MissingFormLabel
- 258
Ljubicic N, Spajic D, Vrkljan M M et al.
The value of ascitic fluid polymorphonuclear cell count determination during therapy
of spontaneous bacterial peritonitis in patients with liver cirrhosis.
Hepatogastroenterology.
2000;
47
1360-1363
MissingFormLabel
- 259
Runyon B A, Hoefs J C.
Spontaneous vs secondary bacterial peritonitis. Differentiation by response of ascitic
fluid neutrophil count to antimicrobial therapy.
Arch Intern Med.
1986;
146
1563-1565
MissingFormLabel
- 260
Fong T L, Akriviadis E A, Runyon B A et al.
Polymorphonuclear cell count response and duration of antibiotic therapy in spontaneous
bacterial peritonitis.
Hepatology.
1989;
9
423-426
MissingFormLabel
- 261
Runyon B A, McHutchison J G, Antillon M R et al.
Short-course versus long-course antibiotic treatment of spontaneous bacterial peritonitis.
A randomized controlled study of 100 patients.
Gastroenterology.
1991;
100
1737-1742
MissingFormLabel
- 262
Bauer T M, Follo A, Navasa M et al.
Daily norfloxacin is more effective than weekly rufloxacin in prevention of spontaneous
bacterial peritonitis recurrence.
Dig Dis Sci.
2002;
47
1356-1361
MissingFormLabel
- 263
Arroyo V, Gines P, Gerbes A L et al.
Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome
in cirrhosis. International Ascites Club.
Hepatology.
1996;
23
164-176
MissingFormLabel
- 264
Salerno F, Gerbes A, Gines P et al.
Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis.
Gut.
2007;
56
1310-1318
MissingFormLabel
- 265
Solanki P, Chawla A, Garg R et al.
Beneficial effects of terlipressin in hepatorenal syndrome: a prospective, randomized
placebo-controlled clinical trial.
J Gastroenterol Hepatol.
2003;
18
152-156
MissingFormLabel
- 266
Sanyal A J, Boyer T, Garcia-Tsao G et al.
A randomized, prospective, double-blind, placebo-controlled trial of terlipressin
for type 1 hepatorenal syndrome.
Gastroenterology.
2008;
134
1360-1368
MissingFormLabel
- 267
Martin-Llahi M, Pepin M N, Guevara M et al.
Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome:
a randomized study.
Gastroenterology.
2008;
134
1352-1359
MissingFormLabel
- 268
Neri S, Pulvirenti D, Malaguarnera M et al.
Terlipressin and albumin in patients with cirrhosis and type I hepatorenal syndrome.
Dig Dis Sci.
2008;
53
830-835
MissingFormLabel
- 269
Ortega R, Gines P, Uriz J et al.
Terlipressin therapy with and without albumin for patients with hepatorenal syndrome:
results of a prospective, nonrandomized study.
Hepatology.
2002;
36
941-948
MissingFormLabel
- 270
Saner F, Kavuk I, Lang H et al.
Terlipressin and gelafundin: safe therapy of hepatorenal syndrome.
Eur J Med Res.
2004;
9
78-82
MissingFormLabel
- 271
Dart A B, Mutter T C, Ruth C A et al.
Hydroxyethyl starch (HES) versus other fluid therapies: effects on kidney function.
Cochrane Database Syst Rev.
2010;
CD007594
MissingFormLabel
- 272
Fabrizi F, Dixit V, Messa P et al.
Terlipressin for hepatorenal syndrome: A meta-analysis of randomized trials.
Int J Artif Organs.
2009;
32
133-140
MissingFormLabel
- 273
Gluud L L, Christensen K, Christensen E et al.
Systematic review of randomized trials on vasoconstrictor drugs for hepatorenal syndrome.
Hepatology.
2010;
51
576-584
MissingFormLabel
- 274
Sagi S V, Mittal S, Kasturi K S et al.
Terlipressin therapy for reversal of type 1 hepatorenal syndrome: a meta-analysis
of randomized controlled trials.
J Gastroenterol Hepatol.
2010;
25
880-885
MissingFormLabel
- 275
Gerbes A L, Huber E, Gulberg V.
Terlipressin for hepatorenal syndrome: continuous infusion as an alternative to i.
v. bolus administration.
Gastroenterology.
2009;
137
1179
; author reply 1179 – 1181
MissingFormLabel
- 276
Hadengue A, Gadano A, Moreau R et al.
Beneficial effects of the 2-day administration of terlipressin in patients with cirrhosis
and hepatorenal syndrome.
J Hepatol.
1998;
29
565-570
MissingFormLabel
- 277
Gerbes A L, Gulberg V, Waggershauser T et al.
Renal effects of transjugular intrahepatic portosystemic shunt in cirrhosis: comparison
of patients with ascites, with refractory ascites, or without ascites.
Hepatology.
1998;
28
683-688
MissingFormLabel
- 278
Guevara M, Gines P, Bandi J C et al.
Transjugular intrahepatic portosystemic shunt in hepatorenal syndrome: effects on
renal function and vasoactive systems.
Hepatology.
1998;
28
416-422
MissingFormLabel
- 279
Brensing K A, Textor J, Perz J et al.
Long term outcome after transjugular intrahepatic portosystemic stent-shunt in non-transplant
cirrhotics with hepatorenal syndrome: a phase II study.
Gut.
2000;
47
288-295
MissingFormLabel
- 280
Wong F, Pantea L, Sniderman K.
Midodrine, octreotide, albumin, and TIPS in selected patients with cirrhosis and type
1 hepatorenal syndrome.
Hepatology.
2004;
40
55-64
MissingFormLabel
- 281
Testino G, Ferro C, Sumberaz A et al.
Type-2 hepatorenal syndrome and refractory ascites: role of transjugular intrahepatic
portosystemic stent-shunt in eighteen patients with advanced cirrhosis awaiting orthotopic
liver transplantation.
Hepatogastroenterology.
2003;
50
1753-1755
MissingFormLabel
- 282
Witzke O, Baumann M, Patschan D et al.
Which patients benefit from hemodialysis therapy in hepatorenal syndrome?.
J Gastroenterol Hepatol.
2004;
19
1369-1373
MissingFormLabel
- 283
Mitzner S R, Stange J, Klammt S et al.
Improvement of hepatorenal syndrome with extracorporeal albumin dialysis MARS: results
of a prospective, randomized, controlled clinical trial.
Liver Transpl.
2000;
6
277-286
MissingFormLabel
- 284
Wong F, Raina N, Richardson R.
Molecular adsorbent recirculating system is ineffective in the management of type
1 hepatorenal syndrome in patients with cirrhosis with ascites who have failed vasoconstrictor
treatment.
Gut.
2010;
59
381-386
MissingFormLabel
- 285
Bannares R, Nevens F, Larsen F S et al.
Extracorporeal liver support with the molecular adsorbent recirculating system (MARS)
in patients with acute-on-chronic liver failure (AOCLF). The RELIEF trail (Abstract).
J Hepatol.
2010;
52
S459-S460
MissingFormLabel
- 286
Rifai K, Ernst T, Kretschmer U et al.
Prometheus – a new extracorporeal system for the treatment of liver failure.
J Hepatol.
2003;
39
984-990
MissingFormLabel
- 287
Rifai K, Kribben A, Gerken G et al.
Extracorporeal liver support by fractionated plasma separation and adsorption (Prometheus)
in patients with acute-on-chronic liver failure (HELIOS study): A prospective randomized
controlled multicenter study (Abstract).
J Hepatol.
2010;
52
S3
MissingFormLabel
- 288
Gonwa T A, Poplawski S, Paulsen W et al.
Pathogenesis and outcome of hepatorenal syndrome in patients undergoing orthotopic
liver transplant.
Transplantation.
1989;
47
395-397
MissingFormLabel
- 289
Seu P, Wilkinson A H, Shaked A et al.
The hepatorenal syndrome in liver transplant recipients.
Am Surg.
1991;
57
806-809
MissingFormLabel
- 290
Lafayette R A, Pare G, Schmid C H et al.
Pretransplant renal dysfunction predicts poorer outcome in liver transplantation.
Clin Nephrol.
1997;
48
159-164
MissingFormLabel
- 291
Restuccia T, Ortega R, Guevara M et al.
Effects of treatment of hepatorenal syndrome before transplantation on posttransplantation
outcome. A case-control study.
J Hepatol.
2004;
40
140-146
MissingFormLabel
- 292
Bundesärztekammer .
Richtlinien zur Organtransplantation gem. § 16 Abs.1 S.1 Nrn. 2, 4 u. 5 TPG.
Dtsch Ärztebl.
2010;
107
A1532-1541
MissingFormLabel
- 293
Davis C L, Feng S, Sung R et al.
Simultaneous liver-kidney transplantation: evaluation to decision making.
Am J Transplant.
2007;
7
1702-1709
MissingFormLabel
- 294
Lieberman F L, Hidemura R, Peters R L et al.
Pathogenesis and treatment of hydrothorax complicating cirrhosis with ascites.
Ann Intern Med.
1966;
64
341-351
MissingFormLabel
- 295
Malagari K, Nikita A, Alexopoulou E et al.
Cirrhosis-related intrathoracic disease. Imaging features in 1038 patients.
Hepatogastroenterology.
2005;
52
558-562
MissingFormLabel
- 296
Kinasewitz G T, Keddissi J I.
Hepatic hydrothorax.
Curr Opin Pulm Med.
2003;
9
261-265
MissingFormLabel
- 297
Kiafar C, Gilani N.
Hepatic hydrothorax: current concepts of pathophysiology and treatment options.
Ann Hepatol.
2008;
7
313-320
MissingFormLabel
- 298
Halank M, Strassburg C P, Hoeper M M.
Pulmonary complications of liver cirrhosis: hepatopulmonary syndrome, portopulmonary
hypertension and hepatic hydrothorax.
Internist.
2010;
51 (Suppl 1)
255-263
MissingFormLabel
- 299
Cardenas A, Arroyo V.
Management of ascites and hepatic hydrothorax.
Best Pract Res Clin Gastroenterol.
2007;
21
55-75
MissingFormLabel
- 300
Cardenas A, Kelleher T, Chopra S.
Review article: hepatic hydrothorax.
Aliment Pharmacol Ther.
2004;
20
271-279
MissingFormLabel
- 301
Huang P M, Chang Y L, Yang C Y et al.
The morphology of diaphragmatic defects in hepatic hydrothorax: thoracoscopic finding.
J Thorac Cardiovasc Surg.
2005;
130
141-145
MissingFormLabel
- 302
Rubinstein D, McInnes I E, Dudley F J.
Hepatic hydrothorax in the absence of clinical ascites: diagnosis and management.
Gastroenterology.
1985;
88
188-191
MissingFormLabel
- 303
Xiol X, Castellote J, Cortes-Beut R et al.
Usefulness and complications of thoracentesis in cirrhotic patients.
Am J Med.
2001;
111
67-69
MissingFormLabel
- 304
Reissig A, Heyne J P, Kroegel C.
Ancillary lung parenchymal findings at spiral CT scanning in pulmonary embolism. Relationship
to chest sonography.
Eur J Radiol.
2004;
49
250-257
MissingFormLabel
- 305
Kocijancic I, Vidmar K, Ivanovi-Herceg Z.
Chest sonography versus lateral decubitus radiography in the diagnosis of small pleural
effusions.
J Clin Ultrasound.
2003;
31
69-74
MissingFormLabel
- 306
Kohan J M, Poe R H, Israel R H et al.
Value of chest ultrasonography versus decubitus roentgenography for thoracentesis.
Am Rev Respir Dis.
1986;
133
1124-1126
MissingFormLabel
- 307
Light R W.
Clinical practice. Pleural effusion.
N Engl J Med.
2002;
346
1971-1977
MissingFormLabel
- 308
Castellote J, Xiol X, Cortes-Beut R et al.
Complications of thoracentesis in cirrhotic patients with pleural effusion.
Rev Esp Enferm Dig.
2001;
93
566-575
MissingFormLabel
- 309
Jones P W, Moyers J P, Rogers J T et al.
Ultrasound-guided thoracentesis: is it a safer method?.
Chest.
2003;
123
418-423
MissingFormLabel
- 310
Gordon C E, Feller-Kopman D, Balk E M et al.
Pneumothorax following thoracentesis: a systematic review and meta-analysis.
Arch Intern Med.
2010;
170
332-339
MissingFormLabel
- 311
Romero S, Candela A, Martin C et al.
Evaluation of different criteria for the separation of pleural transudates from exudates.
Chest.
1993;
104
399-404
MissingFormLabel
- 312
Burgess L J, Maritz F J, Taljaard J J.
Comparative analysis of the biochemical parameters used to distinguish between pleural
transudates and exudates.
Chest.
1995;
107
1604-1609
MissingFormLabel
- 313
Light R W, Macgregor M I, Luchsinger P C et al.
Pleural effusions: the diagnostic separation of transudates and exudates.
Ann Intern Med.
1972;
77
507-513
MissingFormLabel
- 314
Mittal B R, Maini A, Das B K.
Peritoneopleural communication associated with cirrhotic ascites: scintigraphic demonstration.
Abdom Imaging.
1996;
21
69-70
MissingFormLabel
- 315
Bhattacharya A, Mittal B R, Biswas T et al.
Radioisotope scintigraphy in the diagnosis of hepatic hydrothorax.
J Gastroenterol Hepatol.
2001;
16
317-321
MissingFormLabel
- 316
Ajmi S, Hassine H, Guezguez M et al.
Isotopic exploration of hepatic hydrothorax: ten cases.
Gastroenterol Clin Biol.
2004;
28
462-466
MissingFormLabel
- 317
Huang P M, Han Y Y, Kuo S W et al.
Color Doppler ultrasonography in detecting transdiaphragmatic flow of hepatic hydrothorax:
correlation with thoracoscopic findings.
J Thorac Cardiovasc Surg.
2009;
138
1251-1252
MissingFormLabel
- 318
Tamano M, Hashimoto T, Kojima K et al.
Diagnosis of hepatic hydrothorax using contrast-enhanced ultrasonography with intraperitoneal
injection of Sonazoid.
J Gastroenterol Hepatol.
2010;
25
383-386
MissingFormLabel
- 319
Takayama T, Kurokawa Y, Kaiwa Y et al.
A new technique of thoracoscopic pleurodesis for refractory hepatic hydrothorax.
Surg Endosc.
2004;
18
140-143
MissingFormLabel
- 320
Lin D J, Zhang M, Gao G X et al.
Thoracoscopy for diagnosis and management of refractory hepatic hydrothorax.
Chin Med J.
2006;
119
430-434
MissingFormLabel
- 321
Xiol X, Castellvi J M, Guardiola J et al.
Spontaneous bacterial empyema in cirrhotic patients: a prospective study.
Hepatology.
1996;
23
719-723
MissingFormLabel
- 322
D"Amico G, Garcia-Tsao G, Pagliaro L.
Natural history and prognostic indicators of survival in cirrhosis: a systematic review
of 118 studies.
J Hepatol.
2006;
44
217-231
MissingFormLabel
- 323
Kaplan L M, Epstein S K, Schwartz S L et al.
Clinical, echocardiographic, and hemodynamic evidence of cardiac tamponade caused
by large pleural effusions.
Am J Respir Crit Care Med.
1995;
151
904-908
MissingFormLabel
- 324
Angueira C E, Kadakia S C.
Effects of large-volume paracentesis on pulmonary function in patients with tense
cirrhotic ascites.
Hepatology.
1994;
20
825-828
MissingFormLabel
- 325
Heller B J, Grathwohl M K.
Contralateral reexpansion pulmonary edema.
South Med J.
2000;
93
828-831
MissingFormLabel
- 326
Feller-Kopman D, Berkowitz D, Boiselle P et al.
Large-volume thoracentesis and the risk of reexpansion pulmonary edema.
Ann Thorac Surg.
2007;
84
1656-1661
MissingFormLabel
- 327
Liu L U, Haddadin H A, Bodian C A et al.
Outcome analysis of cirrhotic patients undergoing chest tube placement.
Chest.
2004;
126
142-148
MissingFormLabel
- 328
Colombato L.
The role of transjugular intrahepatic portosystemic shunt (TIPS) in the management
of portal hypertension.
J Clin Gastroenterol.
2007;
41 (Suppl 3)
S344-S351
MissingFormLabel
- 329
Strauss R M, Martin L G, Kaufman S L et al.
Transjugular intrahepatic portal systemic shunt for the management of symptomatic
cirrhotic hydrothorax.
Am J Gastroenterol.
1994;
89
1520-1522
MissingFormLabel
- 330
Chalasani N, Gitlin N.
TIPS for patients with refractory hepatic hydrothorax: what is the take-home message?.
Am J Gastroenterol.
1997;
92
2129-2130
MissingFormLabel
- 331
Gordon F D, Anastopoulos H T, Crenshaw W et al.
The successful treatment of symptomatic, refractory hepatic hydrothorax with transjugular
intrahepatic portosystemic shunt.
Hepatology.
1997;
25
1366-1369
MissingFormLabel
- 332
Degawa M, Hamasaki K, Yano K et al.
Refractory hepatic hydrothorax treated with transjugular intrahepatic portosystemic
shunt.
J Gastroenterol.
1999;
34
128-131
MissingFormLabel
- 333
Conklin L D, Estrera A L, Weiner M A et al.
Transjugular intrahepatic portosystemic shunt for recurrent hepatic hydrothorax.
Ann Thorac Surg.
2000;
69
609-611
MissingFormLabel
- 334
Siegerstetter V, Deibert P, Ochs A et al.
Treatment of refractory hepatic hydrothorax with transjugular intrahepatic portosystemic
shunt: long-term results in 40 patients.
Eur J Gastroenterol Hepatol.
2001;
13
529-534
MissingFormLabel
- 335
Spencer E B, Cohen D T, Darcy M D.
Safety and efficacy of transjugular intrahepatic portosystemic shunt creation for
the treatment of hepatic hydrothorax.
J Vasc Interv Radiol.
2002;
13
385-390
MissingFormLabel
- 336
Wilputte J Y, Goffette P, Zech F et al.
The outcome after transjugular intrahepatic portosystemic shunt (TIPS) for hepatic
hydrothorax is closely related to liver dysfunction: a long-term study in 28 patients.
Acta Gastroenterol Belg.
2007;
70
6-10
MissingFormLabel
- 337
Dhanasekaran R, West J K, Gonzales P C et al.
Transjugular intrahepatic portosystemic shunt for symptomatic refractory hepatic hydrothorax
in patients with cirrhosis.
Am J Gastroenterol.
2010;
105
635-641
MissingFormLabel
- 338
Ikard R W, Sawyers J L.
Persistent hepatic hydrothorax after peritoneojugular shunt.
Arch Surg.
1980;
115
1125-1127
MissingFormLabel
- 339
Ghandour E, Carter J, Feola M et al.
Management of hepatic hydrothorax with a peritoneovenous (Denver) shunt.
South Med J.
1990;
83
718-719
MissingFormLabel
- 340
Falchuk K R, Jacoby I, Colucci W S et al.
Tetracycline-induced pleural symphysis for recurrent hydrothorax complicating cirrhosis.
A new approach to treatment.
Gastroenterology.
1977;
72
319-321
MissingFormLabel
- 341
Milanez Campos J R, Filho L O, Campos Werebe de E et al.
Thoracoscopy and talc poudrage in the management of hepatic hydrothorax.
Chest.
2000;
118
13-17
MissingFormLabel
- 342
Ferrante D, Arguedas de M R, Cerfolio R J et al.
Video-assisted thoracoscopic surgery with talc pleurodesis in the management of symptomatic
hepatic hydrothorax.
Am J Gastroenterol.
2002;
97
3172-3175
MissingFormLabel
- 343
Cerfolio R J, Bryant A S.
Efficacy of video-assisted thoracoscopic surgery with talc pleurodesis for porous
diaphragm syndrome in patients with refractory hepatic hydrothorax.
Ann Thorac Surg.
2006;
82
457-459
MissingFormLabel
- 344
Huang P M, Kuo S W, Lee J M.
Thoracoscopic diaphragmatic repair for refractory hepatic hydrothorax: application
of pleural flap and mesh onlay reinforcement.
Thorac Cardiovasc Surg.
2006;
54
47-50
MissingFormLabel
- 345
Xiol X, Tremosa G, Castellote J et al.
Liver transplantation in patients with hepatic hydrothorax.
Transpl Int.
2005;
18
672-675
MissingFormLabel
- 346
Serste T, Moreno C, Francoz C et al.
The impact of preoperative hepatic hydrothorax on the outcome of adult liver transplantation.
Eur J Gastroenterol Hepatol.
2010;
22
207-212
MissingFormLabel
- 347
Sese E, Xiol X, Castellote J et al.
Low complement levels and opsonic activity in hepatic hydrothorax: its relationship
with spontaneous bacterial empyema.
J Clin Gastroenterol.
2003;
36
75-77
MissingFormLabel
- 348
Ackerman Z, Reynolds T B.
Evaluation of pleural fluid in patients with cirrhosis.
J Clin Gastroenterol.
1997;
25
619-622
MissingFormLabel
- 349
Xiol X, Castellote J, Baliellas C et al.
Spontaneous bacterial empyema in cirrhotic patients: analysis of eleven cases.
Hepatology.
1990;
11
365-370
MissingFormLabel
- 350
Castellote J, Lopez C, Gornals J et al.
Use of reagent strips for the rapid diagnosis of spontaneous bacterial empyema.
J Clin Gastroenterol.
2005;
39
278-281
MissingFormLabel
- 351
Hoffken G, Lorenz J, Kern W et al.
Epidemiology, diagnosis, antimicrobial therapy and management of community-acquired
pneumonia and lower respiratory tract infections in adults. Guidelines of the Paul-Ehrlich-Society
for Chemotherapy, the German Respiratory Society, the German Society for Infectiology
and the Competence Network CAPNETZ Germany.
Pneumologie.
2009;
63
e1-68
MissingFormLabel
- 352
Maskell N A, Davies C W, Nunn A J et al.
U.K. Controlled trial of intrapleural streptokinase for pleural infection.
N Engl J Med.
2005;
352
865-874
MissingFormLabel
Prof. Dr. Alexander L. Gerbes
Med. Klinik und Poliklinik 2, Leber Centrum München, Klinikum der LMU München
Marchioninistr. 15
81377 München
eMail: sekretariat.gerbes@med.uni-muenchen.de